AI can improve cancer outcome predictions by generating synthetic molecular data from routine pathology images, according to new research ...

Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.

Illumina launched the Billion Cell Atlas to train AI on one billion single cells. AstraZeneca, Merck and Lilly are founding ...

N2OFF’s wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for ...

The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...

AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of ...

A new study published in Ecology Letters has uncovered the mechanisms underlying plant community assembly and biodiversity ...

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

Machine learning models reveal that histone marks are predictive of gene expression across human cell types and highlight important nuances between natural control and the effects of CRISPR-Cas9-based ...

LAHORE: Artificial intelligence (AI) is enabling researchers to uncover new cancer applications for widely used medicines by ...

Meta-analysis shows diabetes increases male infertility risk, with inflammation identified as a key underlying mechanism.

AI Impact explores why AI security has outgrown human oversight, plus pricing gains, health care insight and key AI moves in ...